• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
JIN Rui, YAN Ruoning, LU Yuting, SONG Min, HANG Taijun. Identification of related substances of midazolam hydrochloride by LC-MS[J]. Journal of China Pharmaceutical University, 2020, 51(3): 313-326. DOI: 10.11665/j.issn.1000-5048.20200309
Citation: JIN Rui, YAN Ruoning, LU Yuting, SONG Min, HANG Taijun. Identification of related substances of midazolam hydrochloride by LC-MS[J]. Journal of China Pharmaceutical University, 2020, 51(3): 313-326. DOI: 10.11665/j.issn.1000-5048.20200309
shu

Identification of related substances of midazolam hydrochloride by LC-MS

More Information
  • Received Date: March 24, 2020
  • Revised Date: April 27, 2020
    Graphical Abstract
    • Abstract
  • This study aimed to identify the related substances of midazolam hydrochloride by liquid chromatography-mass spectrometry (LC-MS). To separate the related substances of midazolam hydrochloride, gradient elution was performed using acetonitrile and 25 mmol/L of ammonium acetate (pH was adjusted to 5.5 with acetic acid) as mobile phase on Thermo BDS Hypersil C18 column (100 mm × 4.6 mm, 2.4 μm). The accurate mass and elemental composition of the parent ions and their product ions of related substances were determined by electrospray-ionization quadrupole time-of-flight mass spectrometry (ESI-Q-TOF/MS). The structures of the related substances were identified by spectral analysis and process synthesis, and some of them were further confirmed by reference substances. Under the established HPLC condition, midazolam hydrochloride and its related substances were adequately separated, and 22 major related substances were detected and identified by hyphenated techniques in midazolam hydrochloride and its stressed samples, of which 8 were recorded as impurities in the United States Pharmacopeia. The LC-MS techniques can effectively separate and identify the related substances of midazolam hydrochloride and provide reference for the establishment of storage condition, optimization of synthetic processes and quality control.
    • FullText(HTML)
    • References (19)
  • [1]
    . Cochrane Database Syst Rev， 2016（5）： CD009491.
    [2]
    Chen XJ， Mou XQ， He ZY， et al. The effect of midazolam on pain control after knee arthroscopy： a systematic review and meta-analysis［J］. J Orthop Surg Res， 2017， 12（1）： 179.
    [3]
    Grant MC， Kim J， Page AJ， et al. The effect of intravenous midazolam on postoperative nausea and vomiting： a meta-analysis［J］. Anesth Analg， 2016， 122（3）： 656-663.
    [4]
    Reddy SD， Reddy DS. Midazolam as an anticonvulsant antidote for organophosphate intoxication： a pharmacotherapeutic appraisal［J］. Epilepsia， 2015， 56（6）： 813-821.
    [5]
    Shtull-Leber E， Silbergleit R， Meurer WJ. Pre-hospital midazolam for benzodiazepine-treated seizures before and after the rapid anticonvulsant medication prior to arrival trial： a national observational cohort study［J］. PLoS One， 2017， 12（3）： e0173539. doi：10.1371/journal.pone.0173539.
    [6]
    Dao K， Giannoni E， Diezi M， et al. Midazolam as a first-line treatment for neonatal seizures： retrospective study［J］. Pediatr Int， 2018， 60（5）： 498-500.
    [7]
    Ng E， Taddio A， Ohlsson A. Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit［J］. Cochrane Database Syst Rev， 2017， 1（1）： CD002052.
    [8]
    Sivaramakrishnan G， Sridharan K. Nitrous oxide and midazolam sedation： a systematic review and meta-analysis［J］. Anesth Prog， 2017， 64（2）： 59-65.
    [9]
    Santotoribio JD， Parodi Fernández V， Mesa Suárez P. Sedation with midazolam without neurotoxic effects［J］.Med Clin （Barc）， 2018，150（11）：450.
    [10]
    Cheng X， Chen L， Huang LN， et al. Determination of related substances of midazolam syrup by RP-HPLC［J］. Fujian Anal Test（福建分析测试）， 2010， 19（2）： 76-79.
    [11]
    Huang CY， Chen MH， Cai M， et al. Preliminary exploration and structure identification of related substances of midazolam injection by 2D-LC-IT-TOF/MS［J］. Chin J Pharm Anal（药物分析杂志）， 2017， 37（4）： 688-694.
    [12]
    Feng XL， Du G， Hou TY， et al. Characterization of degradation products of midazolam maleate by UHPLC-HR-IT-MSn and NMR［J］. Pharmazie， 2017， 72（2）： 73-80.
    [13]
    Sati B， Sati H， Saklani S， et al. Synthesis of the impurities during the manufacture of bulk drug midazolam and separation of these impurities by HPLC［J］. Acta Pharm， 2013， 63（3）： 385-396.
    [14]
    The United States Pharmacopeia Convention. United States Pharmacopeia 43［S］. Rockville：The United States Pharmacopeia Convention， 2020： 2952-2953．
    [15]
    Guo JF， Shan XY， Shi HL.Graphical synthetic routes of midazolam［J］. Chin J Pharm （中国医药工业杂志）， 2012，43（5）：82-84.
    [16]
    Fu YG， Li L， Li J， et al. Study on conjugated system of midazolam［J］. Chem Bioeng （化学与生物工程）， 2010， 27（10）： 31-32， 36.
    [17]
    Hou XY. Study on the stability of midazolam syrup solution（咪达唑仑糖浆混合液稳定性研究）［D］. Bejing：Peking Union Medical College， 2017.
    [18]
    Yin XY， Wang C， Ming GJ， et al. Identification of the related substances in pioglitazone hydrochloride by hyphenated LC-MS techniques［J］. J China Pharm Univ（中国药科大学学报）， 2017， 48（6）： 701-710.
    [19]
    Ni YL， Han X， Song M， et al. Identification of the related substances of cyclosporin A by LC-MS techniques［J］. J China Pharm Univ（中国药科大学学报）， 2019， 50（4）： 423-437.
    • Related Articles

  • Related Articles

    [1]HOU Kai, LI Ping, ZHANG Jinlian, WANG Fang, YANG Yu. Blood coagulation factor XI: new strategy of targeted anticoagulant therapy[J]. Journal of China Pharmaceutical University, 2024, 55(5): 708-714. DOI: 10.11665/j.issn.1000-5048.2023050101
    [2]YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202
    [3]LIU Yanhong, CHEN Liqing, ZHANG Xintong, GAO Zhonghao, HUANG Wei. Research progress of tumor immunomodulation strategies based on nanodrug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 5-14. DOI: 10.11665/j.issn.1000-5048.2023021501
    [4]WANG Yanmei, YANG Lei, XIN Xiaofei, YIN Lifang. Combination therapy and drug delivery strategies for treatment of non-alcoholic fatty liver disease[J]. Journal of China Pharmaceutical University, 2022, 53(4): 423-432. DOI: 10.11665/j.issn.1000-5048.20220405
    [5]ZHOU Xinyuan, LIU Nan, ZHANG Pan, HUO Meirong. Advances in research on therapeutic strategies of targeting pancreatic cancer stroma[J]. Journal of China Pharmaceutical University, 2021, 52(6): 653-662. DOI: 10.11665/j.issn.1000-5048.20210602
    [6]FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
    [7]YANG Shan, XU Cheng, YAO Jing. Strategies of nano drug delivery system applied in anti-angiogenic therapy[J]. Journal of China Pharmaceutical University, 2019, 50(1): 11-18. DOI: 10.11665/j.issn.1000-5048.20190102
    [8]SONG Ke, PAN Hao, HAN Jiayi, CHEN Lijiang. Nano drug delivery system based strategies to target tumor microenvironment[J]. Journal of China Pharmaceutical University, 2018, 49(4): 392-400. DOI: 10.11665/j.issn.1000-5048.20180402
    [9]SU Zhigui, MO Ran, ZHANG Can. Advances of nano-drug delivery systems overcoming the physiological and pathological barriers of tumor[J]. Journal of China Pharmaceutical University, 2015, 46(1): 28-39. DOI: 10.11665/j.issn.1000-5048.20150103
    [10]KE Xue. Advances in targeted drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(1): 9-15.

  • Cited by

    Periodical cited type(2)

    1. 翟允耀，章晓骅. 化学仿制药制剂开发中晶型研究思路探讨. 药品评价. 2024(02): 131-133 .
    2. 梁霖霖，王志伟，何小双，衡伟利，钱帅，高缘，张建军，魏元锋. 机械外力对中药提取物晶体学固态形式及溶出速率的影响研究——以女贞子提取物为例. 中国药科大学学报. 2024(06): 767-774 . 本站查看

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (278) PDF downloads (535) Cited by(2)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：365829

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return